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Introduction: Studies with strong selection biases propose that alpha-synucleinopathy (AS) spreads upwards and
downwards in the neuraxis from the medulla, that amygdala-dominant AS is strongly associated with Alzheimer’s
disease (AD), and that a more severe involvement of the cerebral cortex is correlated with increasing risk of
dementia. This study examines the association of AS patterns and observed neuropsychological symptoms in brains
of a population-representative donor cohort.
Methods: Brains donated in 2 out of 6 cognitive function and ageing study cohorts (Cambridgeshire and
Nottingham) were examined. Over 80% were >80 years old at death. The respondents were evaluated prospectively
in life for cognitive decline and dementia. Immunocytochemistry for tau and alpha-synuclein (using LB509 by
Zymed Laboratories) was carried out in 208 brains to establish Braak stage and the pattern and severity of AS
following the dementia with Lewy bodies (DLB) consensus recommendations. Dementia, specific neuropsychological
measures as measured using the Cambridge cognitive examination, the presence of hallucinations and Parkinson’s
disease were investigated.
Results: Four patterns of AS were observed: no AS pathology (n = 92), AS pathology following the DLB consensus
guidelines (n = 33, of which five were ‘neocortical’), amygdala-predominant AS (n = 18), and other AS patterns (n = 33).
Each group was subdivided according to high/low neurofibrillary tangles (NFT) Braak stage. Results showed no
association between dementia and these patterns of AS, adjusting for the presence of NFT or not. The risk of visual
hallucinations shows a weak association with AS in the substantia nigra (odds ratio (OR) = 3.2; 95% confidence interval
(CI) 0.5 to 15.5; P = 0.09) and amygdala (OR = 3.0; 95% CI 0.7 to 12.3; P = 0.07). The analysis is similar for auditory
hallucinations in subcortical regions.
Conclusions: Among the whole population of older people, AS does not increase the risks for dementia, irrespective
of Braak stage of NFT pathology. There was no evidence that the pattern of AS pathology in cortical areas was relevant
to the risk of hallucination. In general, the hypothesis that AS as measured using these methods per se is a key
determinant of cognitive clinical phenotypes is not supported.* Correspondence: p.g.ince@sheffield.ac.uk
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Diagnostic protocols for the neuropathological assess-
ment of the ageing brain, for use in both research and
clinical diagnosis, are based on the severity and anato-
mical distribution of lesions [1-3]. There is an expect-
ation that ‘cases’ will be pathologically distinguishable
from unimpaired individuals although the pathologies of
Alzheimer’s disease (AD), Parkinson’s disease (PD) and
Dementia with Lewy bodies (DLB) are routinely present
in normal elderly brain donors [4-8]. Comparison of
brain pathology in AD cases with DLB and PD cases
suggests that Lewy body (LB) pathology contributes
significantly to dementia [9-13]. However, there is no
evidence-based consensus for a threshold of AS that will
distinguish demented from non-demented people [5,14,15].
The prevalence of α-synucleinopathy (AS), the substrate
of LB pathology, is reported to vary between 2% to 12% in
people without dementia at death and from 12% to 61% in
people with dementia [5,14,16-18]. Limited AS in cor-
tical and subcortical areas is variably interpreted as pre-
symptomatic disease [7,19] or non-specific age-related
degeneration.
This previous work on the clinicopathological associa-
tion of alpha-synucleinopathy is based on cohorts de-
rived from secondary referral, memory clinics or
community volunteers. These methods of selection
introduce underestimated biases that prevent extrapola-
tion of the conclusions to the whole population of eld-
erly people. In general the impact of pathology is
exaggerated in such studies [20]. In this study the associ-
ation between AS, AD pathology, dementia, clinical PD
and neuropsychological symptoms was assessed in a
truly population-representative sample free of selection
biases associated with clinical diagnosis, symptoms or
access to health and social care facilities.
Methods
Medical Research Council Cognitive Function and Ageing
Study
The Medical Research Council Cognitive Function and
Ageing Study (MRC CFAS) has been fully described else-
where [21]. It is a longitudinal, prospective, population-
based cohort study initiated in 1989. At each of five centres
in England and Wales random samples of about 2,500
people, 64-years old and older (with an 82% response rate),
agreed to a structured initial interview. Structured inter-
views collected details of sociodemographic status, general
health, Mini Mental State Examination (MMSE) [22] and
functional ability. Approximately 20% of the sample
completed a more detailed diagnostic assessment, inclu-
ding full mood and organicity sections of the Geriatric
Mental State (GMS) Automated Geriatric Examination
for Computer Assisted Taxonomy (AGECAT) [23] and
the Cambridge Cognitive Examination (CAMCOG) [24].Further waves of interviewing (both screening and assess-
ment) were conducted at two, five and nine years after
baseline on the survivors. In a sixth centre 5,200 people,
65-years old and older, were interviewed using the same
assessment interviews with follow-up at one to two, three
to four, five to six, and nine years later. The CFAS Neuro-
pathology Study is based on a brain donor programme
established in 1992. Individuals selected for the assess-
ment interviews were approached by a trained liaison offi-
cer for brain donation. The donation programme was
discussed with the respondent and their family or carer as
appropriate. All participants in the study gave their in-
formed consent. This analysis is based on the burden and
anatomical distribution of AS in all donations from two
MRC CFAS centres before July 2003 (Nottingham and
Cambridgeshire, n = 208). Research was carried out after
approval from the Eastern Multi Centre Research Ethics
Committee based at Papworth Hospitals NHS Trust
(reference 03/5/017).
Postmortem procedure and anatomical sampling
Pathological evaluation of the Neuropathology Study co-
hort had previously been carried out using the Consortium
to Establish a Registry for Alzheimer’s Disease (CERAD)
protocol [1] and each brain was assigned a Braak score for
neurofibrillary tangles [2]. At autopsy samples of brain tis-
sue were removed for frozen storage. The remainder of
the brain was fixed for standardised assessment using
paraffin-embedded tissues. For the evaluation of synuclei-
nopathy a hierarchical sampling strategy was adopted
based on evaluation of the midbrain (substantia nigra),
medulla (dorsal efferent nucleus of the vagus nerve, me-
dullary reticular formation) and amygdala to detect AS
pathology. This method of screening was selected because
literature at the time of the study indicated that no cases
had been reported in which AS was present in any brain
region but absent from these three screening areas
[3,25-29]. If at least one positive α-synuclein immunoreac-
tive profile was found in a screening area five additional
areas were investigated (cingulate gyrus, entorhinal cortex
and hippocampus, frontal cortex, parietal cortex and tem-
poral cortex), comprising the DLB Consensus recommen-
dations for the evaluation of AS [30].
Immunocytochemistry for alpha-synuclein, quantification
Microwave antigen retrieval (citric acid 10 mM pH6) of
6 μm brain sections was followed by immunocyto-
chemistry using a monoclonal antibody to mouse alpha-
synuclein (LB509, Zymed Laboratories Inc; San Francisco,
CA USA; dilution 1/200; incubated at 4°C overnight). In-
cubation with biotinylated secondary antibody (1/250) for
1.5 hours at room temperature was followed by ABC Elite
Mouse IgG reagents (Vector Laboratories, Burlingame,
CA, USA) for one hour. Reaction product was visualised
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to the manufacturer’s protocol. All sections were counter-
stained with haematoxylin and mounted in DPX. Inter-
pretation of the appearances was jointly established with
propidium iodide (PI). Acceptable inter- and intra-rater
reliability was previously reported in this study [31]. AS
pathology was then rated by a single investigator (JZ). The
microscopic field with the highest density of AS was iden-
tified and the number of AS profiles was counted at x200
magnification. Spherical and densely stained structures
were considered to be LB irrespective of intra- or extra-
cellular localisation. Elongated AS-positive profiles were
considered to be Lewy neurites (LN). Two consecutive
sections from each block were assessed and the highest
density score retained for the statistical analysis. In the
final analysis, results were dichotomised to AS present
versus absent.
Each brain was allocated to a pathological category as
shown in Table 1. These categories were based on the
presence or absence of neurofibrillary tangles (NFT) and
AS. NFT pathology was dichotomised on the basis of
Braak stage (Low - stages I-III versus High - stages IV-VI).
AS was divided into three categories based on previous
work in this cohort:
1. Cases that conform to the hierarchy of anatomical
spread of AS implicit in the DLB Consensus
protocol for the evaluation of AS [30], which also
implies that these cases conform to the Braak
staging hypothesis proposed for AS [3]. Some
analyses are based on the stratification of this group
into those with DLB ‘limbic’ and ‘neocortical’ disease
and those with AS confined to midbrain/brainstem
structures;Table 1 Pathology subgroups based on α-synucleinopathy (A
Neuropathology group Criteria
No pathology No AS; Braak stages I
NFT only No AS; Braak stages I
AS At least 1 LB or LN in
AS + high NFT AS + Braak stages IV-
AS + low NFT AS + Braak stages I-II
AS DLB + high NFT AS pattern consistent
AS DLB + low NFT AS pattern consistent
AS Amygdala-predominant + high NFT amygdala-predomina
AS Amygdala-predominant + low NFT amygdala-predomina
AS Other pattern + high NFT AS pattern not consis
Braak stages IV-VI NFT
AS Other pattern + low NFT AS pattern not consis
Braak stages I-III NFT
DLB, dementia with Lewy bodies.2. Cases that conform to ‘amygdala-predominant’ AS
implying that amygdala AS is prominent and that
involvement of neocortical, brainstem and midbrain
structures is limited and patchy [31];
3. Cases with an atypical AS distribution,
predominantly those with mild to severe cortical
involvement in the absence of AS in one of the
lower hierarchic anatomical sites (for example,
substantia nigra, locus ceruleus, dorsal vagus nucleus).
For example, this category includes cases with
prominent AS involvement observed in the substantia
nigra and frontal cortex but not in other investigated
areas, or cases with prominent AS involvement
observed in the vagus nucleus and parietal cortex
only. These also include six cases corresponding to
the ‘cerebral-form of DLB’ [32] where AS was
observed in the neocortex predominantly.
Previous findings in this cohort showed that there was
no association between these different AS staining pat-
terns and Braak stage for NFT [31]. Thirty-two brains
were excluded from the final analysis due to missing
pathological or clinical data.
Dementia and other outcomes
Dementia was defined using a combination of the AGE-
CAT algorithm, death certificates and informant inter-
views, including retrospective informant interviews after
death (RINI). Ten percent of participants were classified
as having unknown dementia status on the basis that
both the time between the last interview and death was
too long to exclude incident dementia (over six months)
and that data collected during informant interviews were
inconclusive. The presence or absence of hallucinationsS) and severity of neurofibrillary tangle (NFT) pathology
Number
-III NFT 49
V-VI NFT 43
any region 84
VI NFT 32
I NFT 52
with DLB Consensus; Braak stages IV-VI NFT 13
with DLB Consensus; Braak stages I-III NFT 20
nt AS pattern: Braak stages IV-VI NFT 9
nt AS pattern: Braak stages I-III NFT 9
tent with DLB consensus or amygdala-predominant AS; 10
tent with DLB consensus or amygdala-predominant AS: 23
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symptoms and informant interview data.Specific neuropsychological measures
General cognitive function was assessed using the MMSE.
A score of 21 or less was used to indicate the likely
presence of dementia. The CAMCOG neuropsychological
battery includes seven areas of cognition: orientation,
language (comprehension and expression), memory (lear-
ning, recent and remote), attention/calculation, praxis,
abstract thinking and perception. Cut-off scores for each
domain subscales were taken as values falling below the
25th percentile cut-point in the whole of the non-
demented MRC CFAS population. Results are presen-
ted for a total CAMCOG score (all seven areas) and
for CAMCOG areas of attention/calculation, language
(comprehension and expression), abstract thinking and
perception. CAMCOG cut-off points were 83 out of a
maximum score of 103, 5 out of 8 (attention/calculation),
25 out of 30 (language), 5 out of 8 (abstract thinking) and
6 out of 8 (perception). Informant and interview data were
analysed for the presence or absence of visual hallucin-
ation, auditory hallucination and a self-reported diagnosis
of Parkinson’s disease.Table 2 Demographics of the respondents
Demographic characteristic All MRC CFAS
(Number = 451)
Cambridgeshire
Nottingham coh
(Number = 20
Sex
Men 188 (41) 123 (5
Women 268 (59) 85 (4
Age at death
70 to 79 89 (19) 40 (1
80 to 89 204 (49) 102 (4
90 to 105 163 (32) 66 (3
Education
<10 years 318 (69) 159 (7
10+ years 138 (31) 49 (2
Social class
Non manual 165 (36) 79 (3
Manual 234 (51) 110 (3
Unclassified/Army 57 (13) 19 (
Dementia statusa
Dementia 242 (53) 105 (5
No dementia 184 (40) 83 (4
Unknownb 30 (7) 20 (1
aDetermined using AGECAT organicity scores, informants interview items and death
the time between the last interview and death was too long to exclude incident de
inconclusive. AS, alpha-synucleinopathy; MRC CFAS, Medical Research Council CognStatistical analysis
MRC CFAS has released data at defined points. For this
study, version 8.2 of the core MRC CFAS dataset and
version 3.3 of the neuropathology dataset were used. All
statistical work was conducted in Stata Software version
9.0 (Stata Corporation, College Station, TX, USA). Odds
ratios and Fischer’s exact (chi squared) tests were ap-
plied to estimate the strength of any association between
two observations. High P-values are associated with a
higher likelihood that there is no significant difference
between compared groups. All P-values are two sided.Results
Demographics and AS staging patterns of the study
cohort
The sample used in this analysis is representative of all
MRC CFAS centres (Table 2). It includes a wide range of
age-related neuropathology and a spectrum of clinical
states including dementia and normal cognition. The sam-
ple contains a high proportion of the ‘oldest-old’ in whom
the burden of dementia and neurodegeneration is highest.
Among the 176 brain donors included in this analysis
the four patterns of AS were distributed as follows: (1)
no AS pathology (n = 92); (2) AS pathology following theand
orts
8)
NFT only
(Number = 43)
AS + NFT
(Number = 32)
AS only
(Number= 52)
9) 10 (23) 16 (50) 21 (40)
1) 33 (74) 16 (50) 31 (60)
9) 5 (12) 4 (12) 15 (29)
9) 19 (44) 16 (50) 28 (54)
2) 19 (44) 12 (48) 9 (17)
6) 33 (77) 26 (81) 35 (67)
4) 10 (23) 6 (19) 17 (33)
8) 17 (39) 12 (37) 17 (33)
3) 21 (49) 16 (50) 30 (58)
9) 5 (12) 4 (13) 5 (9)
0) 30 (70) 24 (75) 18 (34)
0) 12 (28) 6 (19) 27 (53)
0) 1 (2) 2 (6) 7 (13)
certificates; bunknown dementia status was assigned on the basis that both
mentia (over six months) and the data collected from interviews were
itive Function and Ageing Study; NFT, neurofibrillary tangles.
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cortical’); (3) amygdala-predominant AS (n = 18) [28]; (4)
other AS patterns (n = 33). Each group was subdivided ac-
cording to the presence of NFT as defined by NFT Braak
stage as dichotomised to low or high score (Table 1).
AS and dementia or features of DLB
LB pathology was found in 34% of those without dementia
during life and in 45% of those with dementia. The odds
ratio for risk of dementia in association with LB is 1.6
(95% confidence interval 0.8 to 3.0, P = 0.1). There is a sig-
nificant association between self-reported Parkinson’s dis-
ease and the presence of AS in substantia nigra, amygdala
and the parietal neocortex (Table 3). There is also weak
evidence of involvement of the cingulate cortex. These
findings are consistent with the expected associations
from the literature. The risk of visual hallucination in this
population cohort shows weak evidence of an association
with AS in substantia nigra (OR = 3.2; 95% CI 0.5 to 15.5;
P = 0.09) and amygdala (OR = 3.0; 95% CI 0.7 to 12.3;
P = 0.07). The analysis is similar for auditory halluci-
nations in subcortical regions. The odds ratios for visual
hallucinations are higher in cortical regions compared to
those for auditory hallucination but the small sample size
restricts the statistical power of this analysis.
Association between AS staging pattern and
neuropsychological symptoms
An initial analysis (not shown) compared the association
of cognitive outcome variables between cases with neo-
cortical and limbic patterns of AS according to the DLB
Consensus guidelines and those with only brainstem in-
volvement. In this population-based sample, none of the
outcomes were significantly different for these two
groups and they were combined in the analysis as the
‘DLB Consensus pattern’ group. Odds ratios for the asso-
ciation between neuropsychological symptoms and the
different pathology groups are presented in Table 4.
Adjusting for age, education, the presence of any vascu-
lar pathology, or a CAMCOG assessment performed
more than two years before death, did not change the re-
sults. There was no association between AS and dementia
(OR = 0.88; 95% CI 0.35 to 2.22) or between AS and low
MMSE in cases with low NFT Braak stage (OR = 0.96;
95% CI 0.41 to 2.26). There was no additional risk of cog-
nitive impairment when comparing brains with combined
AS and NFT (OR for dementia = 4.63; 95% CI 1.52 to
15.1) to brains with NFT only (OR = 3.68; 95% CI 1.37 to
10.08). Among the three AS pathology groups with low
NFT Braak stage, the group conforming to DLB Consen-
sus guidelines was more likely to be demented (OR = 3.24;
95% CI 0.87 to 13.47). Brains classified as ‘neocortical’
DLB by the DLB Consensus guidelines, irrespective of
NFT (n = 5), included only two with dementia. None ofthe nine brains with amygdala-predominant AS in the ab-
sence of NFT had dementia. These sub-groups are too
small for statistical analysis. The cases with AS only in
neocortical areas (‘cerebral form of DLB’; n = 6) [32],
irrespective of NFT Braak stage, had a high likelihood of
being demented (five of six), and all had low MMSE
scores. However, there was no evidence of an association
between the presence of this ‘cerebral-form of DLB’ and
individual domains of CAMCOG scores. Braak stage in
the five demented cases was: 0 (one case); 3 (one case);
5 (two cases); 6 (one case).
Analysis of the risk associated with sub-threshold per-
formance in individual domains of CAMCOG were not
shown to be elevated above the control ‘no pathology’
group even in cases with high NFT Braak stage or com-
bined AS and high NFT Braak stage. This reflects the
sample sizes and the likely lack of power to detect an ef-
fect. It is interesting that in the AS cases with low NFT
Braak stage the risk of subthreshold performance in the
perceptual domain was increased for those with amyg-
dala predominant disease (OR = 3.11; 95% CI 0.32 to
153.1) and the atypical AS group (OR = 4.15; 95% CI
0.77 to 41.44) but the robustness of this finding needs to
be confirmed in a larger study.
Discussion
We report the clinicopathological correlation of AS in a
cohort of brains from older people donated from a
population-based study. In this cohort of CFAS respon-
dents, a reliable diagnosis of cognitive state at death was
possible in 90%: 40% were non-demented at death and
50% demented. AS was present in 39% of the 208 brains
examined. We have previously shown that AS in the
population does not always conform to the DLB Con-
sensus model of hierarchic spread, or the similar model
implicit in proposed Braak staging of AS [3,30,31]. Only
half of the brains with AS in this sample conform to DLB
Consensus or Braak staging. A further 29% conform to
the more recent concept of amygdala-predominant AS
[33,34]. However, one in five old people with AS show a
pattern that is not typical of either of these models, in-
cluding approximately 3% who have AS largely restricted
to the neocortex.
Previous studies reporting on a relationship between
AS and neurologic and neuropsychological outcomes
generally make a number of assumptions. These include
a systematic hierarchical spread of disease upwards and
downwards in the neuraxis from the medulla, a strong
association between amygdala-predominant AS and
Alzheimer’s disease, and the expectation that more severe
involvement of the cerebral cortex is correlated with in-
creasing risk of dementia [2,25-29,31,33-37]. There is also
emerging evidence that AS is present in aged brains
without neuro-psychiatric disorders or extra-pyramidal
Table 3 Relationship between α-synucleinopathy (AS) and a diagnosis of Parkinson’s disease (PD), visual hallucinations (VH) and auditory hallucinations (AH)
Brain area % (brains showing AS)
No PD (n = 201) PD (n = 7) OR (95% CI) P No VH (n = 196) VH (n = 12) OR (95% CI) P No AH (n = 194) AH (n = 14) OR (95% CI) P
Substantia nigra 11 50 7.8 (1.0 to 60.6) <0.01 12 30 3.2 (0.5 to 15.5) 0.09 11 31 3.5 (0.7 to 13.9) 0.04
Vagus nucleus 21 43 2.9 (0.4 to 17.8) >0.2 21 25 1.2 (0.2 to 5.3) >0.2 22 36 2.2 (0.5 to 7.8) >0.2
Amygdala 22 57 4.7 (0.7 to 33.4) 0.03 22 45 3.0 (0.7 to 12.3) 0.07 22 36 1.9 (0.5 to 6.9) >0.2
Frontal cortex 2 0 2 0 2 0
Temporal cortex 2 0 2 8 4.0 (0.1 to 44.2) >0.2 2 0
Parietal cortex 3 29 11.1 (0.9 to 82.3) <0.01 4 8 2.1 (0.04 to 18.5) >0.2 4 7 1.8 (0.04 to 15.2) >0.2
Hippocampus 2 0 2 0 2 0
Entorhinal cortex 6 0 2.1 (0.04 to 18.2) >0.2 7 0 6 7 1.2 (0.02 to 9.1) >0.2
Cingulate cortex 3 14 5.4 (0.1 to 57.2) >0.2 3 8 2.9 (0.05 to 27.1) >0.2 3 7 2.4 (0.05 to 22.2) >0.2
CI, confidence interval; OR, odds ratio.
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Table 4 Association between neuropsychological symptoms and pathology groups (when compared to associations
with a no pathology group, unadjusted)
Neuropsychological measure High NFT only AS + high NFT AS + low NFT
n N OR 95% CI P n N OR 95% CI P n N OR 95% CI
MMSE score <21 32 43 3.53 (1.30 - 10.01) <0.01 23 32 2.21 (0.81 - 6.27) >0.2 25 52 0.96 (0.41 - 2.26)
Dementia 30 43 3.68 (1.37 - 10.08) <0.01 24 32 4.63 (1.52 - 15.07) <0.01 17 52 0.88 (0.35 - 2.22)
Low CAMCOG Attention 25 43 1.29 (0.41 - 4.27) >0.2 15 32 0.69 (0.21 - 2.32) >0.2 23 52 0.56 (0.20 - 1.54)
Low CAMCOG Languagea 27 43 2.05 (0.56 - 8.46) >0.2 21 32 1.99 (0.49 - 9.68) >0.2 26 52 0.7 (0.24 - 2.02)
Low CAMCOG Abstract thinking 18 43 1.93 (0.68 - 5.51) >0.2 13 32 1.62 (0.53 - 5.02) >0.2 20 52 1.5 (0.57 - 4.00)
Low CAMCOG Perception 27 43 2.33 (0.70 - 8.47) >0.2 16 32 0.83 (0.27 - 2.63) >0.2 31 52 2.01 (0.66 - 6.39)
Low CAMCOG Totalb 29 43 3.67 (0.83 - 22.20) >0.2 19 32 1.44 (0.38 - 6.13) >0.2 26 52 0.82 (0.28 - 2.43)
DLB Consensus + high NFT Amygdala-predominant + high NFT other AS pattern + high NFT
MMSE score <21 10 13 3.21 (0.70 - 19.89) >0.2 7 9 2.24 (0.44 - 14.76) >0.2 6 10 1.44 (0.30 - 7.77)
Dementia 10 13 4.5 (0.96 - 28.04) 0.06 7 9 4.72 (0.77 - 49.99) 0.07 7 10 4.72 (0.77 - 49.99)
Low CAMCOG Attention 7 13 1.45 (0.23 - 16.15) >0.2 4 9 0.41 (0.07 - 2.66) >0.2 4 10 0.55 (0.08 - 4.40)
Low CAMCOG Languagea 9 13 3.41 (0.38 -163.00) >0.2 7 9 2.66 (0.28-130.36) >0.2 5 10 0.95 (0.13 - 11.36)
Low CAMCOG Abstract thinking 4 13 1.2 (0.20 - 6.54) >0.2 5 9 1.88 (0.34 - 10.87) >0.2 4 10 2 (0.29 - 15.30)
Low CAMCOG Perception 8 13 2.07 (0.34 - 22.35) >0.2 5 9 0.65 (0.12 - 3.85) >0.2 3 10 0.39 (0.05 - 2.71)
Low CAMCOG Totalb 8 13 3.03 (0.33 -146.68) >0.2 5 9 0.63 (0.10 - 4.81) >0.2 6 10 2.28 (0.23-114.05)
DLB Consensus + low NFT Amygdala-predominant + low NFT other AS pattern + low NFT
MMSE score <21 13 20 1.39 (0.45 - 4.38) >0.2 1 9 0.12 (0.00 - 1.04 ) >0.2 11 23 1.32 (0.40 - 4.46)
Dementia 12 20 3.24 (0.87 - 13.47) 0.09 0 9 0 (0.00 - 0.62) >0.2 5 23 0.56 (0.13 - 2.09)
Low CAMCOG Attention 10 20 0.83 (0.20 - 3.78) >0.2 1 9 0.07 (0.00 - 0.70) >0.2 12 23 0.83 (0.22 - 3.35)
Low CAMCOG Languagea 9 20 0.57 (0.14 - 2.45) >0.2 5 9 0.95 (0.13 - 11.36) >0.2 12 23 0.76 (0.20 - 3.11)
Low CAMCOG Abstract thinking 6 20 1 (0.24 - 3.91) >0.2 2 9 0.6 (0.05 - 4.29) >0.2 12 23 3 (0.82 -11.68)
Low CAMCOG Perception 9 20 0.93 (0.23 - 4.26) >0.2 6 9 3.11 (0.32-153.14) >0.2 16 23 4.15 (0.77 - 41.44)
Low CAMCOG Totalb 7 20 0.44 (0.10 - 2.01) >0.2 6 9 2.28 (0.23-114.05) >0.2 13 23 0.99 (0.25 - 4.38)
aComprehension and Expression; bover seven CAMCOG domains. AS, alpha-synucleinopathy; CAMCOG, Cambridge Cognitive Examination; CI, confidence interval;
DLB, dementia with Lewy bodies; MMSE, Mini Mental State Examination; NFT, neurofibrillary tangles; OR, odds ratio.
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the fact that the research studies that underpin these
assumptions did not involve the assessment of true
population-based cohorts so that they emerged from, and
have been tested in, cohorts influenced by selection biases
associated with clinical referral, clinical case selection,
hospitalisation or volunteer recruitment strategies, and in
addition, to selection related to the pathological findings.
The possibility therefore arises that inter-individual
variation in pathophysiological responses might ac-
count for the differences seen between disease-based
and population-based observations. It is thus possible
that individuals who develop the clinicopathological
features of a Lewy Body disorder (for example, PD and
DLB) are predisposed to enable hierarchic spread of
synucleinopathy in the brain whereas those chiefly en-
countered in population-based samples, and large un-
selected autopsy series, with atypical distribution of
pathology and absent clinical features somehow resist
such propagation.In the present analysis we show that, among the whole
population of elderly people, AS does not increase the
overall risk for dementia, nor low MMSE or low CAM-
COG scores, irrespective of whether it is associated with
high or low Braak stage of NFT pathology. In AS cases
with a low NFT Braak stage, the group showing patho-
logical spread of AS consistent with the anatomical hier-
archy implicit in the DLB Consensus and Braak staging,
had an increased risk of dementia (OR = 3.24; 95% CI
0.87 to 13.47) compared to the amygdala-predominant
(OR = 0; 95% CI 0.0 to 0.62) and atypical AS groups
(OR = 0.56; 95% CI 0.13 to 2.09). This observation may
in part explain the much more robust correlations with
cognitive status reported in many cohort studies that
largely concentrate on this subgroup of synucleinopathy.
In addition, the cases with the so-called ‘neocortical-form
of DLB’ were very likely to be demented (five of six),
although three of these five cases had a high NFT Braak
stage. Nonetheless, the overall risk of dementia in AS was
not significantly associated with cortical compared to
Zaccai et al. Alzheimer's Research & Therapy  (2015) 7:19 Page 8 of 9subcortical pathology. There was no relationship between
any of the domains of cognition tested within the CAM-
COG battery and AS in specific brain regions either with
high or low NFT Braak stages. There was an expected re-
lationship between self-reported PD and AS in the sub-
stantia nigra although self-reporting of PD in MRC CFAS,
albeit suitable as a screening tool, was also found to iden-
tify a heterogeneous group of movement disorder patients
[39]. This relationship also extended to the amygdala and
parietal cortex with some evidence in the cingulate cortex.
This latter association needs to be tested again with
greater power or by using a different approach. These data
reflect the probable greater concordance of the Braak sta-
ging model in the group with a clinicopathological diagno-
sis of Lewy body PD since the hypothesis was developed
through the study of that disease together with two co-
horts derived from secondary referrals selected on the
basis of either AS pathology in the absence of known cli-
nical disorder or absence of AS pathology in the brainstem
with no clinical record of neurological disease [3]. Finally,
there was evidence for an excess of visual hallucination in
association with AS compared to auditory hallucination
but both were associated with substantia nigra involve-
ment. There was no evidence that the pattern of AS
pathology was relevant to the risk of hallucination and no
relationship with cortical pathology.
Although this is a relatively large cohort, the popula-
tion sampling frame means that the power of the study
is more limited in assessing the relationship between AS
and specific neuropsychological features because the
sample is not enriched either for cases with more exten-
sive AS involving cortical regions or for specific clinical
features such as hallucination. Another point that limits
the conclusions of this study is that AS may have been
underestimated in this group as its pathology in the
olfactory bulb was not included in the initial screening
process [40]. There is also an inherent underestimation
of AS as a result of the study design in that solely two
consecutive sections from each area were included in
the assessment process. However, cortical pathology is
present, and for most clinical correlates equally preva-
lent, in cases with and without these specific features.
Conclusions
In general the hypothesis that AS per se is a key deter-
minant of cognitive clinical phenotypes is not supported
in this rare study of clinicopathological correlations of
AS in a cohort of brains from older people donated from
a population-based study.
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